---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000157"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:26:36.273493+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q2 cash $426.4M; FDA partial hold on azenosertib; CMO resigns

## Summary
- Cash, equivalents and marketable securities $426.4M as of June 30; R&D expense $48.4M (Q2 2024); cash runway into mid-2026.
- FDA placed partial clinical hold on azenosertib June 18 after two deaths in DENALI study; resolution timelines uncertain.
- Discontinued development of BCL-2 inhibitor ZN-d5; combination with azenosertib in AML phase 1 stopped.
- CMO Diana Hausman stepped down effective Aug 8; CEO Kimberly Blackwell appointed Interim CMO; replacement search ongoing.
- Expected 2H milestones: DENALI Cohort 1b topline, azenosertib Phase 1b final results, MAMMOTH data with GSK, others.

## SEC filing metadata
- accession: 0001725160-24-000157
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000157/0001725160-24-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000157/zntl-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000157
- JSON: https://secwatch.observer/filing/0001725160-24-000157.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.